Summary: ProSomnus has advanced multiple strategic initiatives, including FDA registration of its HWO2 buccal mucosal wellness oximeter, launch of the EVO Guided oral appliance, and additional growth financing. The buccal mucosal measurement site may reduce common oximetry errors due to high vascularity, stable temperature, reduced ambient light interference, and lower melanin content. ProSomnus Sleep Technologies today announced significant progress on strategic programs, including the US Food and Drug Administration registration of HWO 2 , a buccal mucosal wellness oximeter. The buccal mucosal region is highly vascular, not prone to contamination from ambient light, temperature stable, and appears to contain less melanin than skin. “When we first began using the ProSomnus EVO Guided Device in early 2025, its thinner design and extended mandibular post gave me pause.